|
Age
|
|
Median [IQR]
|
71 [60, 79]
|
73 [66, 80]
|
78 [70, 82]
|
73 [62, 81]
|
67 [57, 74]
|
73 [63, 80]
|
|
Sex
|
|
Female
|
42,440 (50.8%)
|
36,716 (50.1%)
|
40,818 (49.0%)
|
9529 (63.7%)
|
34,017 (53.8%)
|
163,520 (51.4%)
|
|
Male
|
41,137 (49.2%)
|
36,568 (49.9%)
|
42,465 (51.0%)
|
5430 (36.3%)
|
29,264 (46.2%)
|
154,864 (48.6%)
|
|
Comorbidities
|
|
AF
|
26,090 (31.2%)
|
35,031 (47.8%)
|
44,233 (53.1%)
|
1968 (13.2%)
|
16,844 (26.6%)
|
124,166 (39.0%)
|
|
CAD
|
43,999 (52.6%)
|
63,890 (87.2%)
|
73,417 (88.2%)
|
1771 (11.8%)
|
32,617 (51.5%)
|
215,694 (67.7%)
|
|
CVA
|
15,165 (18.1%)
|
44,157 (60.3%)
|
58,088 (69.7%)
|
3691 (24.7%)
|
8314 (13.1%)
|
129,415 (40.6%)
|
|
PAD
|
10,766 (12.9%)
|
56,137 (76.6%)
|
64,058 (76.9%)
|
4010 (26.8%)
|
6676 (10.5%)
|
141,647 (44.5%)
|
|
Hypertension
|
74,082 (88.6%)
|
72,855 (99.4%)
|
81,502 (97.9%)
|
13,890 (92.9%)
|
60,897 (96.2%)
|
303,226 (95.2%)
|
|
Anemia
|
7609 (9.1%)
|
30,174 (41.2%)
|
33,804 (40.6%)
|
14,415 (96.4%)
|
10,224 (16.2%)
|
96,226 (30.2%)
|
|
Diabetes
|
281 (0.3%)
|
73,081 (99.7%)
|
0 (0%)
|
2597 (17.4%)
|
63,263 (100.0%)
|
139,222 (43.7%)
|
|
Obesity
|
2854 (3.4%)
|
25,323 (34.6%)
|
1688 (2.0%)
|
259 (1.7%)
|
36,812 (58.2%)
|
66,936 (21.0%)
|
|
Renal failure
|
3585 (4.3%)
|
31,489 (43.0%)
|
16,081 (19.3%)
|
6059 (40.5%)
|
9854 (15.6%)
|
67,068 (21.1%)
|
|
COPD
|
19,045 (22.8%)
|
37,795 (51.6%)
|
46,656 (56.0%)
|
4779 (31.9%)
|
18,113 (28.6%)
|
126,388 (39.7%)
|
|
Cancer
|
11,227 (13.4%)
|
18,097 (24.7%)
|
25,782 (31.0%)
|
4947 (33.1%)
|
7599 (12.0%)
|
67,652 (21.2%)
|
|
Liver disease
|
4506 (5.4%)
|
13,861 (18.9%)
|
8447 (10.1%)
|
3212 (21.5%)
|
8353 (13.2%)
|
38,379 (12.1%)
|
|
Peptic ulcer
|
2274 (2.7%)
|
5168 (7.1%)
|
5418 (6.5%)
|
1074 (7.2%)
|
2089 (3.3%)
|
16,023 (5.0%)
|
|
Dementia
|
4708 (5.6%)
|
5905 (8.1%)
|
10,913 (13.1%)
|
1897 (12.7%)
|
1567 (2.5%)
|
24,990 (7.8%)
|
|
Depression
|
7950 (9.5%)
|
15,019 (20.5%)
|
14,723 (17.7%)
|
3947 (26.4%)
|
9647 (15.2%)
|
51,286 (16.1%)
|
|
Alcohol misuse disorder
|
2335 (2.8%)
|
1862 (2.5%)
|
2845 (3.4%)
|
866 (5.8%)
|
1480 (2.3%)
|
9388 (2.9%)
|
|
No. of comorbidities at baseline
|
|
2 or less
|
31,692 (37.9%)
|
0 (0%)
|
0 (0%)
|
374 (2.5%)
|
2773 (4.4%)
|
34,849 (10.9%)
|
|
3 to 4
|
46,386 (55.5%)
|
1413 (1.9%)
|
12,859 (15.4%)
|
6939 (46.4%)
|
27,130 (42.9%)
|
94,727 (29.8%)
|
|
5 to 6
|
5453 (6.5%)
|
23,548 (32.1%)
|
46,257 (55.5%)
|
6426 (43%)
|
27,668 (43.7%)
|
109,352 (34.3%)
|
|
7 to 8
|
46 (0.1%)
|
33,594 (45.8%)
|
20,804 (25%)
|
1151 (7.7%)
|
5540 (8.8%)
|
61,135 (19.2%)
|
|
Over 9
|
0 (0%)
|
14,729 (20.1%)
|
3363 (4%)
|
69 (0.5%)
|
160 (0.3%)
|
18,321 (5.8%)
|
|
Inpatient diagnosis (vs. outpatient diagnosis)
|
38,052 (45.5%)
|
40,079 (54.7%)
|
45,411 (54.5%)
|
8057 (53.9%)
|
31,845 (50.3%)
|
163,444 (51.3%)
|
|
Business line
|
|
Medicare Advantage
|
50,158 (60.0%)
|
58,336 (79.6%)
|
63,766 (76.6%)
|
10,467 (70.0%)
|
37,752 (59.7%)
|
220,479 (69.2%)
|
|
Commercial
|
33,419 (40.0%)
|
14,948 (20.4%)
|
19,517 (23.4%)
|
4492 (30.0%)
|
25,529 (40.3%)
|
97,905 (30.8%)
|
|
Race
|
|
White
|
60,104 (71.9%)
|
48,509 (66.2%)
|
61,596 (74.0%)
|
9517 (63.6%)
|
41,694 (65.9%)
|
221,420 (69.5%)
|
|
Black
|
10,277 (12.3%)
|
12,043 (16.4%)
|
9772 (11.7%)
|
2828 (18.9%)
|
11,322 (17.9%)
|
46,242 (14.5%)
|
|
Hispanic
|
5200 (6.2%)
|
6786 (9.3%)
|
4711 (5.7%)
|
1162 (7.8%)
|
4916 (7.8%)
|
22,775 (7.2%)
|
|
Asian
|
2064 (2.5%)
|
1332 (1.8%)
|
1619 (1.9%)
|
398 (2.7%)
|
947 (1.5%)
|
6360 (2.0%)
|
|
Missing
|
5932 (7.1%)
|
4614 (6.3%)
|
5585 (6.7%)
|
1054 (7.0%)
|
4402 (7.0%)
|
21,587 (6.8%)
|
|
Education
|
|
Less than 12 grade
|
213 (0.3%)
|
333 (0.5%)
|
202 (0.2%)
|
50 (0.3%)
|
249 (0.4%)
|
1047 (0.3%)
|
|
High school diploma
|
26,027 (31.1%)
|
27,893 (38.1%)
|
27,614 (33.2%)
|
5239 (35.0%)
|
23,724 (37.5%)
|
110,497 (34.7%)
|
|
Less than bachelor degree
|
44,827 (53.6%)
|
37,696 (51.4%)
|
44,452 (53.4%)
|
7643 (51.1%)
|
33,086 (52.3%)
|
167,704 (52.7%)
|
|
Bachelor degree plus
|
11,994 (14.4%)
|
6811 (9.3%)
|
10,511 (12.6%)
|
1918 (12.8%)
|
5801 (9.2%)
|
37,035 (11.6%)
|
|
Missing
|
516 (0.6%)
|
551 (0.7%)
|
503 (0.6%)
|
109 (0.7%)
|
421 (0.7%)
|
2101 (0.7%)
|
|
Income (in US dollars)
|
|
< $40,000
|
23,672 (28.3%)
|
25,282 (34.5%)
|
27,664 (33.2%)
|
4762 (31.8%)
|
20,137 (31.8%)
|
101,517 (31.9%)
|
|
$40,000–$74,000
|
21,529 (25.8%)
|
19,643 (26.8%)
|
21,849 (26.2%)
|
3600 (24.1%)
|
16,672 (26.3%)
|
83,293 (26.2%)
|
|
$75,000–$124,999
|
17,020 (20.4%)
|
12,704 (17.3%)
|
14,310 (17.2%)
|
2435 (16.3%)
|
12,621 (19.9%)
|
59,090 (18.6%)
|
|
$125,000–$199,999
|
6551 (7.8%)
|
3684 (5.0%)
|
4341 (5.2%)
|
891 (6.0%)
|
4102 (6.5%)
|
19,569 (6.1%)
|
|
$200,000+
|
3602 (4.3%)
|
1360 (1.9%)
|
1957 (2.3%)
|
423 (2.8%)
|
1642 (2.6%)
|
8984 (2.8%)
|
|
Missing
|
11,203 (13.4%)
|
10,611 (14.5%)
|
13,162 (15.8%)
|
2848 (19.0%)
|
8107 (12.8%)
|
45,931 (14.4%)
|
|
Medication at baseline
|
|
Cardioselective beta-blockers
|
26,936 (32.2%)
|
32,949 (45.0%)
|
36,051 (43.3%)
|
4351 (29.1%)
|
22,095 (34.9%)
|
122,382 (38.4%)
|
|
Non-cardioselective beta-blockers
|
11,602 (13.9%)
|
13,169 (18.0%)
|
11,643 (14.0%)
|
1882 (12.6%)
|
9463 (15.0%)
|
47,759 (15.0%)
|
|
ACEi/ARBs
|
33,005 (39.5%)
|
41,120 (56.1%)
|
37,711 (45.3%)
|
5925 (39.6%)
|
31,073 (49.1%)
|
148,834 (46.7%)
|
|
MRA
|
3091 (3.7%)
|
3893 (5.3%)
|
2864 (3.4%)
|
733 (4.9%)
|
3233 (5.1%)
|
13,814 (4.3%)
|
|
Thiazide
|
9444 (11.3%)
|
12,071 (16.5%)
|
10,997 (13.2%)
|
1964 (13.1%)
|
9809 (15.5%)
|
44,285 (13.9%)
|
|
Loop diuretics
|
19,171 (22.9%)
|
28,629 (39.1%)
|
24,597 (29.5%)
|
4772 (31.9%)
|
21,361 (33.8%)
|
98,530 (30.9%)
|
|
Potassium-sparing diuretics
|
44 (0.1%)
|
90 (0.1%)
|
71 (0.1%)
|
23 (0.2%)
|
72 (0.1%)
|
300 (0.1%)
|
|
Double therapy (ACEi/ARBs + any beta-blocker)
|
19,842 (23.7%)
|
27,291 (37.2%)
|
24,207 (29.1%)
|
2990 (20.0%)
|
18,142 (28.7%)
|
92,472 (29.9%)
|
|
Triple therapy (ACEi/ARB + any beta blocker + MRA)
|
1530 (1.8%)
|
1905 (2.6%)
|
1273 (1.5%)
|
179 (1.2%)
|
1475 (2.3%)
|
6362 (2.0%)
|
